Reuters logo
BRIEF-Vical reports outcome of Phase 1 trial of VL-2397
May 2, 2017 / 10:01 PM / 5 months ago

BRIEF-Vical reports outcome of Phase 1 trial of VL-2397

May 2 (Reuters) - Vical Inc

* Vical highlights successful outcome of Phase 1 trial of VL-2397 novel antifungal during its research and development day Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below